Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 15/20 | 0.55 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | MST1R | Q04912 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476312 | 0.97 | FGFR2 (0.60) | FGFR2METFLT3KITPDGFRA | |
| SCHEMBL4471424 | 0.95 | MET (0.54) | FGFR2METFLT3KITPDGFRA | |
| SCHEMBL4471703 | 0.93 | MET (0.56) | METFLT3KITPDGFRAKDR | |
| SCHEMBL4472742 | 0.92 | MET (0.62) | METFLT3KITPDGFRAKDR | |
| SCHEMBL4475416 | 0.92 | FGFR2 (0.54) | FGFR2METFLT3KITPDGFRA | |
| SCHEMBL4478109 | 0.91 | MET (0.59) | METFLT3KITKDRMST1R | |
| SCHEMBL4480530 | 0.91 | FGFR2 (0.66) | FGFR2METKITPDGFRAKDR | |
| SCHEMBL4472236 | 0.91 | FGFR2 (0.66) | FGFR2METKITPDGFRAKDR | |
| SCHEMBL4475392 | 0.90 | MET (0.52) | FGFR2METFLT3KITPDGFRA | |
| SCHEMBL4486831 | 0.90 | FLT3 (0.64) | FGFR2METFLT3KITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | claimed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1447405-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | FGFR1, FGFR2, FGFR3 | FGFR2 2/4885MET 6/4885FLT3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.